Retinoblastoma gene product antibodies and uses therefor
CA 2013544 C · Owner: Fung, Yuen Kai · Inventors: Fung, Yuen Kai; T'Ang, Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses a method of determining the prognosis of a cancer patient by determining the presence or absence of Retinoblastoma gene product in tumor antibodies which specifically bind to the hydrophilic c-terminus of the retinoblastoma protein are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 1990 and granted February 6, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.